Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration

Abstract

The number of trials meeting the ESMO-MCBS threshold for clinical benefit has improved over time. However, fewer than half of RCTs supporting FDA approval meet the threshold for clinically meaningful benefit.